Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy

REFERENCES

• Campion , E. W. , Glynn , R. J. and Delabry , L. O. 1987 . Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study . Am. J. Med. , 82 : 421 – 426 .
   PubMedGoogle Scholar
• Becker , M. A. , Schumacher , H. R. Jr. , Wortmann , R. L. , MacDonald , P. A. , Eustace , D. , Palo , W. A. , Streit , J. and Joseph-Ridge , N. 2005 . Febuxostat compared with allopurinol in patients with hyperuricemia and gout . N. Engl. J. Med. , 353 : 2450 – 2461 .
   PubMed Web of Science ®Google Scholar
• Shoji , A. , Yamanaka , H. and Kamatani , N. 2004 . A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy . Arthritis Rheum. [Arthritis Care Res.] , 51 : 321 – 325 .
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz , F. , Calabozo , M. , Pijoan , J. I. , Herrero-Beites , A. M. and Ruibal , A. 2002 . Effect of urate lowering therapy on the velocity of size reduction of tophi in chronic gout . Arthritis Rheum. , 47 : 356 – 360 .
   PubMed Web of Science ®Google Scholar
• Terkeltaub , R. A. 2003 . Gout. N . Engl. J. Med. , 349 : 1647 – 1655 .
   PubMed Web of Science ®Google Scholar
• Li-Yu , J. , Clayburne , G. , Sieck , M. , Beutler , A. , Rull , M. , Eisner , E. and Schumacher , H. R. Jr. 2001 . Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? . J. Rheumatol. , 28 : 577 – 580 .
   PubMed Web of Science ®Google Scholar
• Yamanaka , H. , Togashi , R. , Hakoda , M. , Terai , C. , Kashiwazaki , S. , Dan , T. and Kamatani , N. 1998 . Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment . Adv. Exp. Med. Biol. , 431 : 13 – 18 .
   PubMed Web of Science ®Google Scholar
• Schumacher , H. R. Jr. , Becker , M. A. , Wortmann , R. L. , MacDonald , P. A. , Hunt , B. , Streit , J. , Lademacher , C. and Joseph-Ridge , N. 2005 . Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: The 28-week APEX study . Arthritis Rheum. , 52 : S680
   Google Scholar
• Ganson , N. J. , Kelly , S. J. , Scarlett , E. , Sundy , J. S. and Hershfield , M. S. 2006 . Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase . Arthritis Res. Ther. , 8 ( 1 ) : R12
   Web of Science ®Google Scholar
• Borstad , G. C. , Bryant , L. R. , Abel , M. P. , Scroggie , D. A. , Harris , M. D. and Alloway , J. A. 2004 . Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis . J. Rheumatol. , 31 : 2429 – 2432 .
   PubMed Web of Science ®Google Scholar
• Riedel , A. A. , Nelson , M. , Joseph-Ridge , N. , Wallace , K. , MacDonald , P. and Becker , M. 2004 . Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims . J. Rheumatol. , 31 : 1575 – 1581 .
   PubMed Web of Science ®Google Scholar
• Schumacher , H. R. Jr. , Becker , M. A. , Palo , W. , Streit , J. , MacDonald , P. A. and Joseph-Ridge , N. 2005 . Tophaceous gout-quantitative evaluation by direct physical measurement . J. Rheumatol. , 32 : 2368 – 2372 .
   PubMed Web of Science ®Google Scholar
• Fam , A. G. 1995 . Should patients with interval gout be treated with urate lowering drugs? . J. Rheumatol. , 22 : 1621 – 1623 .
   PubMed Web of Science ®Google Scholar